1 / 19

Sustained Dexamethasone Drug Delivery System

Sustained Dexamethasone Drug Delivery System. Ozurdex and Novadur Implant. First approved pharmacotherapy for macular edema following BRVO and CRVO. Dr. Bharti Kashyap Kashyap Memorial Eye Hospital. A biodegradable dexamethasone implant Drug incorporated into polymer matrix

delling-ull
Download Presentation

Sustained Dexamethasone Drug Delivery System

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sustained Dexamethasone Drug Delivery System Ozurdex and Novadur Implant First approved pharmacotherapy for macular edema following BRVO and CRVO Dr. Bharti Kashyap Kashyap Memorial Eye Hospital

  2. A biodegradable dexamethasone implant • Drug incorporated into polymer matrix • Sustained medication release • Polymer matrix gradually breaks down into inert compounds • Extruded form is implanted with an applicator – the NOVADUR™ implant • Self-sealing wound

  3. NOVADUR™implant • Rod shaped tiny implant • 0.45 mm in diameter and 6 mm in length • Contains 0.7mg of Dexamethasone (preservative free) • Novadur is a proprietary and innovative drug delivery system (DDS). • Dexamethasone embedded in an inactive biodegradable PLGA matrix. (60/40 drug/polymer)

  4. Applicator and NOVADUR™ implant

  5. Drug Release From Biodegradable Implants Three Phases of Release Surface Release

  6. Drug Release From Biodegradable Implants Three Phases of Release Diffusion

  7. Drug Release From Biodegradable Implants Three Phases of Release Bulk Erosion

  8. Lactic Acid Glycolic Acid Drug Delivery Technology Water and Carbon Dioxide Biodegradable Implant Gradually Transforms Into Water and Carbon Dioxide

  9. Changes in Polymer Matrix Over Time Before Implantation After 3 Weeks

  10. Implanted with 22-gauge applicator • Through the pars plana • Wound is self-sealing • No sutures required • Implant does not need to be sutured into place

  11. Inflammation: a key component in the pathogenesis of retinal disease1,2 Retinal vein occlusion (RVO)1 Uveitis1 Inflammation Neovascularisation Vascular leakage Retinal disease Wet age-related macular degeneration (wet AMD)2 Diabetic retinopathy (DR)/diabetic macular edema (DME)1 • Johnson MW. Am J Ophthalmol 2009;147:11–21; • Nowak JZ. Pharmacol Rep 2006;58:353–63.

  12. Healthy Retinal Microvessel Vascular Disease • Diabetes • CRVO/ BRVO • Vasodilation • Leukostasis • Diapedesis • Permeability • Inflammatory proteins Macular Edema PathophysiologyCorticosteroid-Based Therapies Primary Inflammatory Disease • Uveitis VEGF • Inflammatory Mediator • IL-1, 6, 8 • TNF-Alpha

  13. Corticosteroid-Based Therapies Corticosteroids inhibit the inflammatory response to a variety of inciting agents. They inhibit the edema formation, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, deposition of collagen, and scar formation associated with inflammation. They stabilize endothelial cells tight junctions, inhibit the synthesis of VEGF, prostaglandins & other key cytokines.

  14. Corticosteroid-Based Therapies Arachidonic acid is released from membrane phospholipids by phospholipase A2 . It is postulated that lipocortinscontrol the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.

  15. Phospholipase A2 . lipocortins Prostaglandins Leukotrienes Arachidonic acidCorticosteroids

  16. Healthy Retinal Microvessel Vascular Disease • Diabetes • CRVO/ BRVO Corticosteroids • Vasodilation • Leukostasis • Diapedesis • Permeability • Inflammatory proteins Macular Edema PathophysiologyCorticosteroid-Based Therapies Primary Inflammatory Disease • Uveitis VEGF • Inflammatory Mediator • IL-1 • TNF-Alpha

  17. Relative Potencies of Corticosteroids Table 59-2 Goodman & Gilman 9th Edition *approximated from the literature

  18. Desired characteristics of an implantable intravitreal drug delivery system • Controlled, sustained drug release • Simple insertion procedure • Biodegradable implant (does not need to be removed) • Long-term safety

  19. Thank You

More Related